$696,665,954

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

healthactiveONGOING · MOD OF 2020 CONTRACT

WORK BEGAN2020-05-18·LATEST ACTION2026-06-24·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50120C00092_7505_-NONE-_-NONE-

Award description

US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS.

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Funds U.S.-based advanced manufacturing of active pharmaceutical ingredients for COVID-19 medicines and future pandemic threats.

Sub-sectors

pharmaceutical-manufacturingpandemic-preparednessapi-production

Why this matters

Secures domestic production capacity for essential medicines, reducing reliance on foreign supply chains during health emergencies.

Supply-chain signal

Strengthens U.S. pharmaceutical manufacturing base by establishing domestic API production; reduces dependence on imports from China and India.

U.S.–China competition angle

Directly counters U.S. vulnerability to Chinese and Indian API supply disruptions; part of broader effort to reshore critical pharmaceutical manufacturing.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-17. Cost: $0.002894.

Period of performance

Start

2020-05-18

End

2027-01-13

Status

activein 197 days

Recipient

PHLOW CORP.

UEI ZZN7NVV7JKG9

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50120C00092_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.